The Other Side: Beijing Reportedly Feared Trump Might Goad PLA Into Attack As Early As October 2020
Michael Roberts Blog — blogging from a Marxist economist
China at a turning point?
Michael Roberts
The Intercept
How the U.S. Derailed an Effort to Prosecute Its Crimes in Afghanistan
Alice Speri
Sputnik International (putting the cart before the horse)
Putin: 'Hysteria, Confusion' in Europe's Gas Markets Caused by Premature Shift to Alternative Energy
Oriental Review
US Meddling In Nicaraguan Affairs
Leonard Savin
Counterpunch (why the US is underrepresented)
Inside the Pandora Papers
Chuck Collins
The Pandora Papers Reveal How the Super-Rich Shaft the Rest of Us
Chuck Collins
Jacobin (the one thing elites fear most)
The French Revolution Was the Beginning of the Modern World
Sputnik International (what could go wrong with a speculative vehicle that has no intrinsic worth?)
Cryptocurrency Sees Massive Surge in India, Propels Growth in Asian Market, Says Report
India Punchline
Reflections on Events in Afghanistan-24
M. K. Bhadrakumar | retired diplomat with the Indian Foreign Service
The French Revolution Was the Beginning of the Modern World
Jeremy Popki
Cryptocurrency Sees Massive Surge in India, Propels Growth in Asian Market, Says Report
Reflections on Events in Afghanistan-24
M. K. Bhadrakumar | retired diplomat with the Indian Foreign Service
Update: Framing Lumber Prices Up Year-over-year
Bill McBride
The Intercept (the bezzle)
Merck Sells Federally Financed Covid Pill to U.S. for 40 Times What It Costs to MakeSharon Lerner
1 comment:
Merck Sells Federally Financed Covid Pill to U.S. for 40 Times What It Costs to Make
The article is misleading because it assumes that Merck shareholders should be happy with a 10% return on a single successful drug when the shareholder return is across all drugs Merck is working on, including the failed ones that never make it to market.
As for returns for pharma companies:
I know we're all supposed to be cheery going into the holidays, but I have some bad news: Legacy biopharma companies are still in a rut.
Or at least that's what the experts over at Deloitte have to say in a new report finding that, for the top 12 biopharma companies, the return on investment for R&D has fallen to a dismal 1.8%.
That's a decade-long low, and somehow even lower than last year's 1.9% ROI (for comparison, the number stood at 10.1% in 2010).
The reasons are plentiful. Among them: A tougher regulatory environment and an ever-shifting R&D picture which now favors smaller, leaner firms over the giants of old. And even within that narrative, things are complicated, according to Deloitte's Neil Lesser.
"The current model is not a sustainable one for success," Lesser told Fortune in an interview.
source: Big Pharma’s Return on Investment Plummets to a Dismal 10-Year Low
The link to the Deloitte study is here: Seeds of change - Measuring the return from pharmaceutical innovation 2020
Post a Comment